Literature DB >> 16792535

Mutations affecting the replication capacity of the hepatitis B virus.

J Sheldon1, B Rodès, F Zoulim, A Bartholomeusz, V Soriano.   

Abstract

The genetic variability of the hepatitis B virus (HBV) encounters two compounding forces: a high viral copy number produced during active replication and the lack of proofreading activity in the HBV polymerase, resulting in a high mutational rate. A large pool of quasispecies is generated in which the fittest virus, i.e. the virus that replicates best, becomes the dominant species. Immune and antiviral selection pressures result in vaccine/immunoglobulin escape mutants and antiviral resistant variants. Viruses encoding changes associated with antiviral resistance often have reduced replication in vitro, but the accumulation of additional mutations helps restore viral fitness. These compensatory mutations may occur not only in the polymerase gene but also in other genes such as the overlapping envelope gene, the precore gene, or in regulatory regions such as the basal core promoter. In this report we aim to review the new findings that have appeared in recent months.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16792535     DOI: 10.1111/j.1365-2893.2005.00713.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  35 in total

Review 1.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

Review 2.  The underlying mechanisms for the "simultaneous HBsAg and anti-HBs serological profile".

Authors:  R A A Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-12       Impact factor: 3.267

3.  Different Variants in Reverse Transcriptase Domain Determined by Ultra-deep Sequencing in Treatment-naïve and Treated Indonesian Patients Infected with Hepatitis B Virus.

Authors:  Widya Wasityastuti; Yoshihiko Yano; Dewiyani Indah Widasari; Laura Navika Yamani; Neneng Ratnasari; Didik Setyo Heriyanto; Rina Okada; Toshihito Tanahashi; Yoshiki Murakami; Takeshi Azuma; Yoshitake Hayashi
Journal:  Kobe J Med Sci       Date:  2016-06-16

4.  Naturally occurring core protein mutations compensate for the reduced replication fitness of a lamivudine-resistant HBV isolate.

Authors:  Yongmei Zhang; Hu Zhang; Junjie Zhang; Jiming Zhang; Haitao Guo
Journal:  Antiviral Res       Date:  2019-03-19       Impact factor: 5.970

5.  Microarray for hepatitis B virus genotyping and detection of 994 mutations along the genome.

Authors:  Marie Gauthier; Bertrand Bonnaud; Maud Arsac; Fabien Lavocat; Jérôme Maisetti; Alan Kay; François Simon; Fabien Zoulim; Guy Vernet
Journal:  J Clin Microbiol       Date:  2010-09-08       Impact factor: 5.948

6.  Entecavir as specific antiviral therapy in selected cases of severe acute hepatitis B.

Authors:  Oana Streinu-Cercel; Anca Streinu-Cercel; Liliana Lucia Preoţescu; Adrian Streinu-Cercel
Journal:  Germs       Date:  2012-03-01

7.  Prevalence and significance of Hepatitis B reverse transcriptase mutants in different disease stages of untreated patients.

Authors:  Jinxin Zheng; Zheng Zeng; Duyi Zhang; Yanyan Yu; Fang Wang; Calvin Q Pan
Journal:  Liver Int       Date:  2012-08-13       Impact factor: 5.828

8.  Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay.

Authors:  Evelien Libbrecht; Joke Doutreloigne; Hilde Van De Velde; Man-Fung Yuen; Ching-Lung Lai; Fred Shapiro; Erwin Sablon
Journal:  J Clin Microbiol       Date:  2007-10-03       Impact factor: 5.948

Review 9.  Atypical serological profiles in hepatitis B virus infection.

Authors:  Robério A A Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-11-29       Impact factor: 3.267

10.  Drug-related mutational patterns in hepatitis B virus (HBV) reverse transcriptase proteins from Iranian treatment-naïve chronic HBV patients.

Authors:  Mostafa Mahabadi; Mehdi Norouzi; Seyed Moayyed Alavian; Katayoon Samimirad; Talat Mokhtari Azad; Esmaeil Saberfar; Mahmood Mahmoodi; Fatemeh Ramezani; Hadi Karimzadeh; Reza Malekzadeh; Ghodrat Montazeri; Azim Nejatizadeh; Masood Ziaee; Farshid Abedi; Behrooz Ataei; Majid Yaran; Babak Sayad; Mohammad Hossein Somi; Gholamreza Sarizadeh; Ismaeil Sanei-Moghaddam; Fariborz Mansour-Ghanaei; Houshang Rafatpanah; Mohammad Amin Pourhosseingholi; Hossain Keyvani; Ebrahim Kalantari; Mehdi Saberifiroozi; Mohammad Ali Judaki; Shiva Ghamari; Maryam Daram; Zeinab Fazeli; Zahra Goodarzi; Abolfazl Khedive; Abdolvahab Moradi; Seyed Mohamad Jazayeri
Journal:  Hepat Mon       Date:  2013-01-20       Impact factor: 0.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.